☆ 4.6 Article

Neoadjuvant Chemoradiotherapy versus Chemotherapy for Gastroesophageal Junction Adenocarcinoma; Which Is the Optimal Treatment Option?

CANCERS (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Surgery

Postoperative and Pathological Outcomes of CROSS and FLOT as Neoadjuvant Therapy for Esophageal and Junctional Adenocarcinoma An International Cohort Study From the Oesophagogastric Anastomosis Audit (OGAA)

Summary: This study aimed to compare the postoperative and pathological outcomes between CROSS and FLOT in EAC patients. The study found that CROSS had a higher 90-day mortality rate compared to FLOT, mainly due to cardio-pulmonary complications. Additionally, CROSS had higher rates of pathologic complete response and margin-negative resections compared to FLOT. Further research is needed to understand the causes and mechanisms of the higher mortality rate with CROSS and its impact on long-term survival.

ANNALS OF SURGERY (2023)

添加到收藏夹

Article Surgery

Extent of Lymphadenectomy and Long-term Survival in Esophageal Cancer

Eivind Gottlieb-Vedi et al.

Summary: In esophageal cancer surgery, removing more lymph nodes can improve survival, but after reaching a certain number, further lymphadenectomy may decrease survival. A population-based cohort study in Sweden and Finland found that patients who had 4-30 lymph nodes removed had higher survival rates compared to those who had only 1 lymph node removed, especially for patients with advanced T-stages (T3/T4) and those who did not receive neoadjuvant therapy, removing 21-30 lymph nodes showed the best result.

ANNALS OF SURGERY (2023)

添加到收藏夹

Article Oncology

Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

R. Obermannova et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Surgery

CROSS Versus FLOT Regimens in Esophageal and Esophagogastric Junction Adenocarcinoma A Propensity-Matched Comparison

Noel E. Donlon et al.

Summary: This study compared the effects of two different regimens in the treatment of locally advanced esophageal adenocarcinoma and evaluated factors such as tolerance, toxicity, sarcopenia, and pulmonary function. The results showed that both regimens had similar survival rates and operative outcomes, but the CROSS regimen increased the risk of respiratory failure and atrial fibrillation.

ANNALS OF SURGERY (2022)

添加到收藏夹

Article Surgery

An International Cohort Study of Prognosis Associated With Pathologically Complete Response Following Neoadjuvant Chemotherapy Versus Chemoradiotherapy of Surgical Treated Esophageal Adenocarcinoma

Jonathan Cools-Lartigue et al.

Summary: This international cohort study compares the survival rates of esophageal adenocarcinoma patients with pCR following neoadjuvant treatment and finds that different treatment schemes have different impacts on 5-year OS and RFS, raising questions about the validity of using pCR as an oncological surrogate.

ANNALS OF SURGERY (2022)

添加到收藏夹

Article Oncology

Evolution of Esophagectomy for Cancer Over 30 Years: Changes in Presentation, Management and Outcomes

S. Michael Griffin et al.

Summary: This study evaluated changing trends in presentation, management, and outcomes for patients undergoing surgical treatment for esophageal cancer over a 30-year period. Results showed significant improvements in long-term outcomes, mortality, and length of stay, despite an increase in complications, attributed to various factors including perioperative chemo(radio)therapy and improved patient selection.

ANNALS OF SURGICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Health-related quality of life one year after the diagnosis of oesophageal cancer: a population-based study from the Swedish National Registry for Oesophageal and Gastric Cancer

Berit Sunde et al.

Summary: A Swedish study found that patients with esophageal cancer reported low function scores and severe symptoms 1 year after diagnosis, regardless of receiving curative or palliative management. Patients who underwent surgery had more issues with diarrhea, while those treated with chemoradiotherapy had more frequent dysphagia.

BMC CANCER (2021)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Ronan J. Kelly et al.

Summary: In patients with resected esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy, adjuvant therapy with nivolumab significantly improved disease-free survival compared to placebo.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

The Real R0: A Resection Margin Smaller Than 0.1 cm is Associated with a Poor Prognosis After Oncologic Esophagectomy

Penelope St-Amour et al.

Summary: This study evaluated the impact of different R statuses after oncologic esophagectomy on survival and recurrence. The results showed that R0 patients had better survival outcomes than R0+ and R1 patients. R0+ resection had a lower long-term recurrence risk, and R status was independently associated with DFS. Both R0+ and R1 patients had more adverse histologic features and experienced more distant and locoregional recurrence.

ANNALS OF SURGICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Higher lymph node harvest in patients with a pathologic complete response after neoadjuvant therapy for esophageal cancer is associated with improved survival

Waseem Lutfi et al.

JOURNAL OF SURGICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

The Prognostic Value of the Number of Harvested Negative Lymph Nodes in Patients Treated by Esophagectomy With or Without Neoadjuvant Chemoradiation

Maximilian Brunner et al.

ANTICANCER RESEARCH (2020)

添加到收藏夹

Article Oncology

RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction-a randomized phase III joint study of the AIO, ARO and DGAV

Sylvie Lorenzen et al.

BMC CANCER (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial

G. A. von Dobeln et al.

DISEASES OF THE ESOPHAGUS (2019)

添加到收藏夹

Article Medicine, General & Internal

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Salah-Eddin Al-Batran et al.

LANCET (2019)

添加到收藏夹

Article Oncology

Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study

Bo Jan Noordman et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study

S. R. Markar et al.

ANNALS OF ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial

Michael Stahl et al.

EUROPEAN JOURNAL OF CANCER (2017)

添加到收藏夹

Article Gastroenterology & Hepatology

Comparative Quantitative Lymph Node Assessment in Localized Esophageal Cancer Patients After R0 Resection With and Without Neoadjuvant Chemoradiation Therapy

Danica N. Giugliano et al.

JOURNAL OF GASTROINTESTINAL SURGERY (2017)

添加到收藏夹

Article Oncology

Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival

Lucas Goense et al.

JOURNAL OF SURGICAL ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Cancer of the Esophagus and Esophagogastric Junction: An Eighth Edition Staging Primer

Thomas W. Rice et al.

JOURNAL OF THORACIC ONCOLOGY (2017)

添加到收藏夹

Article Oncology

ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS)

J. V. Reynolds et al.

BMC CANCER (2017)

添加到收藏夹

Article Oncology

A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction

F. Klevebro et al.

ANNALS OF ONCOLOGY (2016)

添加到收藏夹

Article Oncology

ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286)

Jens Hoeppner et al.

BMC CANCER (2016)

添加到收藏夹

Article Oncology

Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation

F. Klevebro et al.

EJSO (2015)

添加到收藏夹

Article Medicine, General & Internal

Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer

P. van Hagen et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

Article Oncology

Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial

Bryan H. Burmeister et al.

EUROPEAN JOURNAL OF CANCER (2011)

添加到收藏夹

Article Oncology

Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric Junction

Michael Stahl et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

添加到收藏夹

Article Surgery

Classification of surgical complications - A new proposal with evaluation in a cohort of 6336 patients and results of a survey

D Dindo et al.

ANNALS OF SURGERY (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.